Sino Biopharmaceutical Limited(SBMFF)
USD --+0.00%
Reward55Moderate
Risk23Low
📊75%Data
10.0% dividend yield · Revenue growing 11% YoY
SBMFF
+0.0 · +0.00%
USD · PINK
Sino Biopharmaceutical Limited | Healthcare
Dividend King
Market Cap:13.91Bn
ℹ️
Reward Rating
55
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
23
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SBMFF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Sino Biopharmaceutical Limited?

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China.

SBMFF · Verdict

Solid reward · low risk

SBMFF scores well on cash flow and balance sheet with no major weaknesses flagged in the model.

Based on 88% data coverage

SBMFF · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow89/100

    20% free-cash-flow margin

  • Balance sheet85/100

    Interest covered 17.5×

  • Profitability76/100

    12% net margin · 15% ROE

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Sino Biopharmaceutical Limited?

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 13.91B, and a P/E ratio of 25.9x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (55)

The scoring profile indicates moderate reward potential, with profitability and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap13.91B
P/E Ratio25.93
Dividend Yield10.00%
52 Week High1.24
52 Week Low0.4414
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding18B
No. of Employees23,056
IndustryBiotechnology
ExchangePINK
Beta0.808
CurrencyUSD · Reports in CNY